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INTRODUCTION
The glial cell line-derived neurotrophic factor (GDNF)
has been suggested to be a candidate treatment for Parkin-
son’s disease (PD) (1, 2). Recent in vivo data suggests that
1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment might
enhance GDNF mRNA and protein expression in the stria-
tum of adult rats (3). 1,25(OH)2D3 has also been shown to
attenuate the hypokinesia and neurotoxicity induced by 6-
hydroxydopamine in rats (4).
The genomic mechanism of vitamin D is mediated through
the vitamin D receptor (VDR) (5). Since the presence of the
vitamin D specific nuclear binding in the brain and spinal
cord was reported, there has been accumulated evidence sug-
gesting that both the mRNA encoding the VDR and the pro-
tein itself are present in the nervous system (6-8). The human
VDR gene contains eight coding exons and three alternative
5′ non-coding exons spanning more than 75 kb of the DNA
on chromosome 12 (9). The VDR belongs to the nuclear hor-
mone receptor superfamily, and modulates the transcription
of the target genes in response to 1,25(OH)2D3 (10). 
Although several animal studies indicate the potential use
of 1,25(OH)2D3 in neurodegenerative diseases, the role of
VDR in neurodegeneration has not been clarified and the
association between VDR polymorphisms and these diseases
has received little attention. 
The effect of the VDR genotypes on PD along with their
possible importance in predisposing certain individuals to PD
prompted us to evaluate the association between the VDR
genotype and PD. This study examined the polymorphisms
of the VDR gene intron 8 (BsmI) in order to understand the
role of the VDR gene in the susceptibility to PD in Koreans.
The possible interactions of the VDR gene in terms of gen-
der, the age at onset, clinical expression, and dopa-respon-
siveness were also investigated. 
MATERIALS AND METHODS
Eighty-five PD patients (30 men and 55 women, mean
age: 64.55±8.86 yr) were evaluated by a neurologist and
diagnosed with idiopathic PD based on the presence of two
or more of the cardinal features of PD (tremor, rigidity, and
bradykinesia), as well as by the lack of signs not related to
PD. The secondary forms of parkinsonism were excluded.
However, no neuropathological investigations were carried
out to define the Lewy body pathology because the patients
are still alive. All the PD patients included in this study were
sporadic based on pedigree analysis. The local ethics commit-
tee approved this study, and all the subjects provided informed
consent. 
The age at onset was categorized into early-onset (<50 yr)
Joong-Seok Kim, Yeong-In Kim, 
Christopher Song*, Injin Yoon, 
Jeong-Wook Park, Young-Bin Choi, 
Hee-Tae Kim
� , Kwang-Soo Lee
Department of Neurology, The Catholic University of
Korea, Seoul, Korea; Division of Biology and Medicine,
Brown University*, RI, U.S.A.; Department of 





Department of Neurology, Kangnam St. Mary Hospital,
505 Banpo-dong, Seocho-gu, Seoul 137-701, Korea
Tel : +82.2-590-2720, Fax : +82.2-599-9686
E-mail : ks1007@cmc.cuk.ac.kr
495
J Korean Med Sci 2005; 20: 495-8
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Association of Vitamin D Receptor Gene Polymorphism and 
Parkinson’ s Disease in Koreans
1 ,25-dihydroxyvitamin D3 (1,25(OH)2D3), which is the biologically active form of
vitamin D, has anti-inflammatory effects and can prevent experimental Parkinson’s
disease (PD). 1,25(OH)2D3 exerts most of its actions only after it binds to its specif-
ic nuclear receptors. Eighty-five Korean patients with PD and 231 unrelated healthy
individuals were evaluated to determine if vitamin D receptor gene (VDRG) BsmI
polymorphisms were markers for the susceptibility to PD in Korean patients. Each
polymorphism was detected using polymerase chain reaction (PCR)-based restric-
tion analysis. In addition, the relationship between the BsmI polymorphisms and
the clinical manifestations of PD was evaluated. Overexpression of the b allele
(91.2 vs. 85.7%; p=0.069) and homozygote bb (84.7 vs. 72.7%; p=0.043) was
found in the PD patients compared with the controls. These results show for the
first time an association between PD and a VDRG polymorphism, which might be
involved in the pathogenesis of PD, or in the linkage disequilibrium of the VDRG to
another pathogenic gene locus.
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or late-onset (>70 yr), respectively (11). In order to determine
the levodopa-responsiveness, the levodopa test was performed
in the morning during a fasting state. All the patients were
first rated using the unified Parkinson’s disease rating scale
(UPDRS) motor subscale, then challenged with a single dose
of 250/25 levodopa/carbidopa and re-rated 1 hr later. The
dopa-responsiveness was defined as a minimum 30% improve-
ment in the scores (12). The UPDRS was also used to assess
the severity of the motor symptoms and signs. An average
global tremor score as well as the mean score for the complex
of postural instability and gait difficulty (PIGD) was calcu-
lated as previously described (13). The tremor-predominant
group was defined as those patients with a mean tremor
score/mean PIGD score ≥1.5. The PIGD group included
all patients with a ratio ≤1.0.
The control group consisted of 231 unrelated individuals,
who were mainly recruited from the health examination clinic
of the Kangnam St. Mary Hospital. The control subjects were
screened to ensure that there was no history of neurological
and psychiatric disorders. The control individuals had an age
and gender distribution similar to the patients. 
The genomic DNA was extracted from the peripheral blood
using a Genomic DNA isolation reagent kit (QIAamp� kit,
Pel-Freez� Clinical Systems). The polymerase chain reaction
(PCR) for the intron 8 polymorphisms was performed using
a PCR thermocycler (ThermoHybaid PCR Sprint, Thermo
Electron Corporation, U.S.A.) and BsmI restriction enzyme
(Roche). The BsmI VDR polymorphism was tested as des-
cribed previously (9). The primers flanking the BsmI restric-
tion site are as follows: forward primer, 5′ -CAA CCA AGA
CTA CAA GTA CCG CGT CAG TGA-3′ and backward
primer, 5′ -AAC CAG CGG GAA GAG GTC AAG GG-3′ .
The BsmI restriction polymorphism revealed two possible
alleles, allele B (absence of a restriction site) and b(presence of
a restriction site). The genotypes were defined as BB (absence
of restriction site on both alleles, one band at 825 bp), bb
(presence of a restriction site on both alleles, two bands at
650 and 175 bp), or Bb (heterozygous, three bands at 825,
650, and 175 bp). 
The allelic and genotypic distributions of the patients and
controls were compared. In addition, the following compar-
isons were performed: the allelic distribution between the
early-onset group and the late-onset group, the tremor group
and PIGD group, the dopa-responsive group and dopa-non-
responsive group. The results were compared using a chi-
square test for statistical significance. Calculations were per-
formed using SPSS for Windows version 11.0 (SPSS Inc.,
Chicago, IL, U.S.A.). A p value <0.05 was considered sig-
nificant. 
RESULTS
The gender distribution and the mean age of the PD patients
and control subjects were similar (Table 1). Table 2 shows
that among the PD patients, two patients (2.4%) had the
VDR genotype BB, 11 patients (12.9%) had Bb, and 72
(84.7%) had bb. Among the 231 control subjects, the VDR
genotype BB was identified in 3 (1.3%), Bb in 60 (26%),
and bb in 168 subjects (72.7%). The VDR genotype bb was
significantly more common in the PD patients than in the
control subjects. The allelic frequency in the PD patients was
15 (8.8%) with the homozygote B and 155 (91.2%) with
the homozygote b, whereas the distribution for the control
group was 66 (14.3%) with the homozygote B and 396 with
PD, Parkinson’s disease; UPDRS, Unified Parkinson’s disease rating
scale; H & Y, Hoehn & Yahr.
PD group Control group
No. 85 231
Age (yr) 64.55±8.86 62.05±10.44 
(range 44-83) (range 43-92)
Onset age (yr) 60.69±10.57
Male 30 (35.3%) 80 (34.6%) 
Disease duration (yr) 3.97±3.76 -
UPDRS part 1 2.95±2.74 -
part 2 10.68±7.12 -
Part 3 21.06±14.01 -
H & Y staging 1.93±0.98 -
Table 1. Clinical characteristics of the Parkinson’s disease patients
and healthy control subjects




PD group Control group p
Genotype frequency 0.043*
BB 2 (2.4) 3 (1.3)
Bb 11 (12.9) 60 (26.0)
bb 72 (84.7) 168 (72.7)
Allele frequency 0.069
�
B 15 (8.8) 66 (14.3)
b 155 (91.2) 396 (85.7)
Table 2. Distribution of the VDR genotyping in the Parkinson’s
disease patients and healthy control subjects
The values represent the number of patients with the percentages in




Tremor group PIGD group p
Genotype frequency 0.044*
BB 1 (2.2)  1 (2.9)
Bb 10 (22.2) 1 (2.9)
bb 34 (75.6) 33 (94.3)
Allele frequency 0.051
�
B 12 (13.3) 3 (4.3)
b 78 (86.7) 67 (95.7)
Table 3. Relationship between the VDR genotyping and the
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the homozygote b (85.7%).  
Among the 85 patients, the bb genotype was overexpressed
in the PIGD predominant PD patients (94.3%) than in the
tremor predominant PD patients (75.6%) (Table 3). The male
to female ratio, the age at onset, and the dopa-responsiveness
of the patient groups with and without the bb genotype were
similar (Table 4). 
DISCUSSION
Most efforts to identify the sequence variations in the VDR
gene have focused on the 3′ regulatory region because it is
close to the anonymous markers used mainly in association
studies. Three adjacent restriction fragment length polymor-
phism (RFLP) for BsmI, ApaI, and TaqI, which are located
near the 3′ end of the gene, is known to be involved in regu-
lating expression, particularly through the control of mRNA
stability (14). Recent studies have suggested a differential
luciferase activity for the two 3′ UTR-variants, which are
linked to the two most frequent haplotypes, “baT” and “BAt”
(9), and a tendency for the BAt haplotype to display some-
what higher of mRNA expression levels than baT (15). At
another level, the result by analyzing the in vivo responses to
treatment demonstrated a trend for the BAt haplotype to dis-
play a somewhat better response than baT (16, 17). Although
the influences of this linkage disequilibrium on the VDR pro-
tein function and signaling is largely unknown, it is tempt-
ing to speculate that individuals with the BAt haplotype have
higher numbers of VDR in the target cells, which confer these
target cells a better response to vitamin D. 
In view of what has been discussed above, a BsmI polymor-
phism in intron 8 of the VDR gene can be an intriguing can-
didate for PD. This study is the first to show an association
between the VDR gene polymorphisms and PD. This study
found that the bb genotype was more common in those PIGD
predominant PD patients compared with the tremor pre-
dominant PD patients and the controls.
It was suggested that PD is not a homogenous entity, but
is divisible into two subtypes (a tremor predominant group
and a PIGD-predominant group) according to the clinical
features as assessed by the components of the UPDRS (18).
The PIGD-dominant group had poorer responsiveness to
dopaminergic replacement therapy, a rapid progression of
motor disabilities and a poor prognosis compared to the tre-
mor-dominant group (13, 18). Therefore, it is possible that
different neuronal mechanisms are involved in the develop-
ment of the major symptoms in PD. In this study, the dis-
tribution of BsmI polymorphisms in the tremor predominant
group was similar to the control group, whereas in the PIGD-
dominant group did not. Although the functional signifi-
cance of the VDR gene in PIGD predominant PD is still
unclear, this study indicates a possible role for the VDR gene
in the development of nigrostriatal neuronal loss leading to
specific parkinsonian symptoms.  
However, care should be taken when interpreting the results
of this study because the distribution of the VDR genotype
at intron 8 BsmI shows ethnic variations. In this study, the
distribution of the VDR genotype in healthy Korean sub-
jects (BB 1.3%, Bb 26%, bb 72.7%) was similar to that in
Japanese subjects (BB 3.2%, Bb 25.3%, bb 71.6%) (19). In
contrast, Morrison et al. reported the BB genotype in 18.4%,
Bb in 52.9%, and bb in 28.7% of healthy controls with Cau-
casian British-Australian ancestry (20). Suppose that the bb
homozygosity for the BsmI genotype is a genetic risk factor
for PD, the high frequency of the bb genotype observed in
this study may be some contradiction to the lower incidence
of PD in Asians (21,22). 
It should be noted that no firm pathophysiological con-
clusions could be drawn from this genetic association study.
A possible explanation is that the VDR gene polymorphism
is a marker of the linkage disequilibrium with another gene,
which is actually responsible for the observed association. Fur-
thermore, generalizing these results might be limited because
this study population is small. Since the evidence for an asso-
ciation between PD and the VDR gene polymorphisms is
based on a BsmI RFLP alone, the distribution of other poly-
morphisms in the VDR gene, such as ApaI, TaqI and FokI,
will need to be analyzed in order to confirm these results. In
addition, the role of a VDR gene polymorphism should be
further examined in other populations in order to confirm
another susceptibility gene for PD and to determine more
adequate strategies for treating PD.
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